Table 1. Clinical Data and CCT values in MS patients and Control Groups.
| MS Patients | ||||
|---|---|---|---|---|
| Characteristic | Control Subjects | Whole group | RR-MS | P-MS |
| Sample size | 44 | 80 | 45 | 35 |
| Male-to-Female ratio | 10/34 | 30/50 | 14/31 | 16/19 |
| Age yrs. | 50.7 (13.12) | 47.5 (9.05) | 45.3 (9.02) | 51.1 (9.18) |
| EDSS (IQR)* | 5.25 (3.5) | 3.5 (3) | 6 (2.5) | |
| Disease duration yrs. | 13.5 (0.96) | 11.9 (1.10) | 15.1 (1,64) | |
| Age at disease onset yrs. | 35.2 (1.97) | 32.9 (1.26) | 35.2 (1.79) | |
| CCT s | 2.8 (0.51) | 4.8 (1.27) | 4.7 (0.17) | 5.1 (0.23) |
| Therapy: | ||||
| No therapy | 34 | 16 | 18 | |
| Natalizumab | 10 | 6 | 4 | |
| Glatiramer acetate | 12 | 8 | 4 | |
| Azathioprine | 5 | 2 | 3 | |
| Interferon β-1a or β-1b | 18 | 12 | 6 | |
| Other therapies | 1 | 1 | 0 | |
Data are means with standard deviations in parentheses.
* For EDSS median and IQR are instead reported. Other therapy is 4-aminopyridine.